Caracterización molecular de los carcinomas nasosinusales y sus implicaciones clínicas

López, Fernando; Llorente, José Luís; Costales, María; García‐Inclán, Cristina; Pérez-Escuredo, Jhudit; Álvarez-Marcos, César; Hermsen, Mario; Suárez, Carlos

doi:10.1016/j.otorri.2012.03.002

Cited by 5 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The absence of squamous differentiation distinguishes ITAC from mucoepidermoid carcinoma and adenosquamous carcinoma [49,50,53,54]. Molecular alterations observed in ITACs are mainly mutations in the TP53 genes (60%) [54] and overexpression of EGFR or HER2 (30%) [55][56][57][58]. The rate of TP53 mutations in ITACs is about 60% and, interestingly, it is related to the duration, average and cumulative level of exposure to wood dust [53][54][55].…”

Section: Intestinal Adenocarcinomamentioning

confidence: 99%

Malignant Sinonasal Tumors: Update on Histological and Clinical Management

et al. 2021

View full text Add to dashboard Cite

Tumors of nasal cavity and paranasal sinuses (TuNSs) are rare and heterogeneous malignancies, presenting different histological features and clinical behavior. We reviewed the literature about etiology, biology, and clinical features of TuNSs to define pathologic features and possible treatment strategies. From a diagnostic point of view, it is mandatory to have high expertise and perform an immunohistochemical assessment to distinguish between different histotypes. Due to the extreme rarity of these neoplasms, there are no standard and evidence-based therapeutic strategies, lacking prospective and large clinical trials. In fact, most studies are retrospective analyses. Surgery represents the mainstay of treatment of TuNSs for small and localized tumors allowing complete tumor removal. Locally advanced lesions require more demolitive surgery that should be always followed by adjuvant radio- or chemo-radiotherapy. Recurrent/metastatic disease requires palliative chemo- and/or radiotherapy. Many studies emphasize the role of specific genes mutations in the development of TuNSs like mutations in the exons 4–9 of the TP53 gene, in the exon 9 of the PIK3CA gene and in the promoter of the TERT gene. In the near future, this genetic assessment will have new therapeutic implications. Future improvements in the understanding of the etiology, biology, and clinical features of TuNSs are warranted to improve their management.

show abstract

Section: Intestinal Adenocarcinomamentioning

confidence: 99%

Malignant Sinonasal Tumors: Update on Histological and Clinical Management

et al. 2021

View full text Add to dashboard Cite

show abstract

Development and validation of a nomogram for prognosis of sinonasal squamous cell carcinoma

Quan

Zhang

et al. 2019

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

BackgroundSinonasal squamous cell carcinoma (SNSCC) is a rare malignancy with varied outcomes. The aim of this study was to develop a nomogram for predicting survival of patients with SNSCC.MethodsFrom the Surveillance, Epidemiology, and End Results database, we identified 1766 patients diagnosed with SNSCC between 2004 and 2015. Patients were randomly separated into a training set and a validation set in 4:1 ratio. An external validation was also performed by a set of 74 SNSCC patients who had been treated in our department. We used the training set to build a nomogram based on stratified multivariable Cox proportional hazard models for predicting overall survival. The predictive accuracy and discriminative ability of the nomogram were determined by concordance index and calibration curve.ResultsBased on 1412 cases of the training cohort, our Cox regression analysis revealed that age, marital status, primary site, differentiation, T stage, N classification, M stage, and treatment modalities were associated with overall survival. A nomogram was established based on the results of multivariate analysis. The C‐index values of the nomogram for predicting survival were superior to those of the tumor‐node‐metastasis staging system (0.745 vs 0.679 in the training cohort, 0.752 vs 0.656 in the validation set, and 0.678 vs 0.596 in the external validation set). The calibration plots demonstrated good consistency between the predicted and observed results.ConclusionWe have developed a nomogram to accurately predict the clinical outcomes of SNSCC patients. This model was effective and can help clinicians to improve patient counseling.

show abstract